dna
methyltransferas
emerg
target
treatment
cancer
brain
disord
diseas
current
inhibitor
potenti
applic
therapeut
agent
research
tool
acid
novel
scaffold
previous
identifi
virtual
screen
detect
although
weak
inhibitori
activ
biochem
assay
herein
report
enzym
inhibit
structur
relat
compound
trimethylaurintricarboxyl
acid
show
low
micromolar
inhibit
ic
dock
studi
new
inhibitor
catalyt
domain
suggest
bind
catalyt
site
interact
amino
acid
residu
particip
mechan
dna
methyl
contribut
bind
recognit
addit
good
match
structurebas
pharmacophor
model
recent
develop
inhibitor
trimethylaurintricarboxyl
acid
valuabl
biochem
tool
studi
inhibit
cancer
diseas
relat
dna
methyl
dna
methyl
epigenet
chang
result
addit
methyl
group
posit
cytosin
residu
dna
methyltransferas
enzym
dnmt
mediat
process
date
three
type
dnmt
identifi
human
genom
includ
two
de
novo
methyltransferas
mainten
methyltransferas
abund
among
three
respons
duplic
pattern
dna
methyl
replic
essenti
proper
mammalian
develop
propos
interest
target
experiment
cancer
therapi
dna
methyl
repres
central
mechan
mediat
epigenet
gene
regul
thu
develop
dnmt
inhibitor
provid
novel
opportun
cancer
therapi
worth
noth
epigenet
alter
associ
cancer
also
psychiatr
diseas
human
protein
amino
acid
whose
structur
divid
ntermin
regulatori
domain
ctermin
catalyt
domain
mechan
dna
methyl
schemat
depict
fig
dnmt
form
complex
dna
cytosin
methyl
flip
dna
thiol
catalyt
cystein
act
nucleophil
attack
target
cytosin
gener
coval
intermedi
cytosin
activ
conduct
nucleophil
attack
cofactor
sadenosyllmethionin
sam
form
coval
adduct
sadenosyllhomocystein
sah
attack
assist
transient
proton
cytosin
ring
endocycl
nitrogen
atom
stabil
glutam
residu
arginin
residu
may
particip
stabil
intermedi
make
hydrogen
bond
interact
carbonyl
oxygen
cytosin
coval
complex
methyl
base
dna
resolv
deproton
gener
methyl
cytosin
free
enzym
date
dnmt
inhibitor
develop
clinic
two
drug
nucleosid
analogu
incorpor
dna
caus
coval
trap
subsequ
deplet
dnmt
aza
nucleosid
fda
approv
treatment
myelodysplast
syndrom
demonstr
signific
although
usual
transient
improv
patient
surviv
current
test
mani
solid
cancer
howev
rel
low
specif
character
substanti
cellular
clinic
toxic
increas
number
substanc
report
inhibit
dnmt
repres
dnmt
inhibitor
candid
demethyl
agent
depict
fig
comput
screen
chemic
databas
contribut
discoveri
lead
compound
distinct
scaffold
similarli
molecular
model
dock
play
key
role
understand
mechan
action
number
dnmt
inhibitor
molecular
level
recent
conduct
virtual
screen
nation
cancer
institut
nci
databas
identifi
acid
fig
inhibitor
ic
molecular
dock
acid
homolog
model
catalyt
domain
indic
key
role
carboxyl
acid
bind
recognit
includ
hydrogen
bond
amino
acid
residu
involv
catalyt
mechan
methyl
recent
research
shown
increas
interest
biolog
activ
acid
relat
compound
exampl
acid
also
emerg
experiment
valid
hit
virtual
screen
viral
rna
methyltransferas
promis
drug
target
flavivirus
caus
agent
sever
diseas
dengu
yellow
fever
moreov
independ
virtual
screen
aurintricarboxyl
acid
structur
analogu
acid
identifi
highli
potent
inhibitor
methyltransferas
activ
flavivir
methyltransferas
also
recent
studi
show
aurintricarboxyl
acid
inhibit
two
adometdepend
rna
methyltransferas
sever
acut
respiratori
syndrom
sar
coronaviru
hypothes
trimethylaurintricarboxyl
acid
fig
inhibitor
note
compound
structur
analogu
aurintricarboxyl
acid
acid
moreov
freeli
avail
nci
drug
synthesi
chemistri
branch
fact
may
increas
impact
applic
insight
work
order
test
hypothesi
identifi
novel
dnmt
inhibitor
herein
report
enzym
inhibit
molecular
model
studi
confirm
hypothesi
trimethylaurintricarboxyl
acid
fig
obtain
nci
drug
synthesi
chemistri
branch
inhibit
enzymat
activ
test
use
hotspot
sm
platform
methyltransferas
assay
avail
reaction
biolog
corpor
hotspot
sm
low
volum
radioisotopebas
assay
use
tritiumlabel
adomet
hsam
methyl
donor
dilut
dmso
ad
use
acoust
technolog
labcyt
enzymesubstr
mixtur
nanolit
rang
reaction
initi
addit
hsam
incub
total
final
methyl
substrat
poli
didc
detect
filter
bind
approach
data
analysi
perform
use
graph
prism
softwar
la
jolla
ca
curv
fit
reaction
carri
sadenosyllmethionin
sam
sadenosyllhomocystein
sah
use
standard
posit
control
assay
test
ic
effect
concentr
inhibit
activ
threefold
serial
dilut
start
employ
homolog
model
catalyt
domain
human
recent
develop
group
homolog
model
use
ration
molecular
level
bind
mode
establish
inhibitor
despit
fact
recent
crystallograph
structur
human
recent
publish
vide
infra
structur
correspond
enzym
bound
unmethyl
dna
structur
suitabl
model
smallmolecul
inhibitor
crystallograph
structur
catalyt
loop
open
conform
catalyt
cystein
far
bind
site
therefor
geometri
catalyt
site
repres
catalyt
mechan
dna
methyl
briefli
build
homolog
model
catalyt
domain
human
taken
uniprot
uniprot
id
sequenc
align
base
sequenc
dna
methyltransferas
mhhai
pdb
id
mhaeiii
pdb
id
pdb
id
built
base
templat
structur
use
prime
prime
version
llc
new
york
ny
cofactor
includ
model
dna
doubl
helix
construct
structur
mhhai
variabl
small
loop
gap
fill
knowledgebas
homolog
ab
initio
approach
orchestrar
miss
long
loop
model
use
loop
search
modul
implement
sybyl
loop
show
highest
homolog
lowest
root
mean
squar
deviat
select
side
chain
hydrogen
atom
ad
stabil
homolog
model
valid
check
geometri
use
procheck
homolog
model
coordin
energi
minim
macromodel
macromodel
version
llc
new
york
ny
use
forc
field
water
environ
converg
termin
gradient
kj
mol
hbond
fix
use
shake
algorithm
molecular
dynam
start
conform
obtain
conform
search
macromodel
possibl
tautom
explor
use
ligprep
ligprep
version
llc
new
york
ny
conform
analysi
carri
mont
carlo
multipl
minimum
lowmod
conform
search
method
employ
opl
forc
field
use
gbsa
water
solvat
model
lowest
energi
conform
dock
catalyt
site
homolog
model
use
glide
extra
precis
xp
glide
version
llc
new
york
ny
also
perform
flexibl
dock
lowenergi
conform
gener
conform
analysi
known
inhibitor
use
refer
vide
infra
gener
grid
dock
complex
dna
structur
remov
homolog
model
human
exclud
target
cytosin
shape
properti
catalyt
site
map
onto
grid
default
dimens
center
target
cytosin
best
dock
pose
select
compar
structurebas
pharmacophor
recent
report
inhibitor
dock
protocol
use
recent
develop
bind
model
dnmt
inhibitor
order
experiment
test
hypothesi
inhibitor
enzymat
inhibitori
activ
compound
measur
use
hotspot
sm
platform
methyltransferas
assay
describ
method
show
low
micromolar
inhibit
ic
valu
correspond
doserespons
plot
shown
fig
note
enzymat
inhibitori
activ
better
activ
previous
report
acid
ic
order
ration
put
bind
mode
molecular
level
conduct
molecular
dock
simul
despit
fact
recent
crystallograph
structur
human
recent
publish
structur
correspond
enzym
bound
unmethyl
dna
suitabl
model
smallmolecul
inhibitor
vide
supra
therefor
employ
homolog
model
recent
develop
use
model
sever
establish
inhibitor
cf
method
geometri
catalyt
site
includ
posit
target
cytosin
model
complex
agreement
catalyt
mechan
dna
methyl
detail
provid
elsewher
note
homolog
model
human
use
previous
identifi
novel
inhibitor
studi
mechan
action
smallmolecul
inhibitor
flexibl
dock
studi
perform
glide
xp
follow
protocol
describ
method
efficaci
dock
protocol
recent
demonstr
recent
publish
dock
structurebas
pharmacophor
studi
sever
known
inhibitor
figur
show
threeand
twodimension
represent
optim
dock
model
select
residu
shown
note
deproton
form
expect
aqueou
solut
shown
bind
model
best
dock
conform
gener
flexibl
dock
accord
bind
model
make
hydrogen
bond
interact
phosphat
group
nucleosid
analogu
well
carboxyl
anion
acid
also
make
hydrogen
bond
one
salicyl
acid
moieti
form
hydrogen
bond
network
key
residu
fig
worth
point
seem
play
crucial
role
catalyt
mechan
fig
furthermor
hydrogen
bond
also
predict
inhibitor
could
pharmacophor
second
methylbenzo
acid
moieti
make
hydrogen
bond
cofactor
fig
similar
hydrogen
bond
interact
cofactor
report
aurintricarboxyl
acid
similar
compound
methyltransferas
hydrogen
bond
interact
agreement
interact
found
dock
model
nucleosid
analogu
potent
inhibitor
comparison
optim
bind
mode
represent
show
hydrogen
bond
network
bind
pocket
deproton
form
shown
bind
model
acid
reveal
compound
adopt
differ
dock
posit
bind
pocket
vide
infra
note
dock
score
kcal
mol
better
dock
score
acid
kcal
mol
similar
nucleosid
analogu
data
shown
figur
show
comparison
optim
bind
mode
acid
recent
develop
pharmacophor
hypothesi
known
dnmt
inhibitor
pharmacophor
model
includ
fivepoint
featur
one
neg
charg
n
one
hydrogen
bond
acceptor
one
aromat
ring
r
two
hydrogen
bond
donor
consid
distanc
match
toler
criteria
commonli
accept
pharmacophor
model
one
carboxyl
acid
group
acid
match
neg
charg
featur
fig
contrast
bind
posit
match
consid
distanc
match
toler
aromat
ring
r
hydrogen
bond
donor
interact
hydrogen
bond
acceptor
interact
pharmacophor
hypothesi
fig
result
support
experiment
observ
better
inhibitor
acid
seem
like
aurintricarboxyl
acid
also
inhibit
preliminari
dock
studi
show
aurintricarboxyl
acid
fig
similar
bind
mode
make
almost
interact
catalyt
site
figur
show
predict
bind
mode
aurintricarboxyl
acid
catalyt
domain
bind
model
trimethyl
analog
shown
comparison
note
deproton
form
ligand
expect
aqueou
solut
shown
bind
model
addit
calcul
bind
score
aurintricarboxyl
acid
kcal
mol
also
better
bind
score
acid
kcal
mol
remain
determin
experiment
enzymat
inhibit
aurintricarboxyl
acid
collect
result
support
impair
correct
locat
dna
catalyt
site
steric
hindranc
site
interact
residu
involv
recognit
freeli
avail
ncidtp
valuabl
biochem
tool
studi
inhibit
cancer
diseas
relat
dna
methyl
report
enzym
inhibit
molecular
model
studi
trimethylaurintricarboxyl
acid
catalyt
site
human
low
micromolar
inhibitor
human
enzymat
molecular
model
studi
confirm
hypothesi
compound
potent
inhibitor
acid
structur
relat
compound
molecular
dock
studi
catalyt
domain
indic
make
hydrogen
bond
interact
amino
acid
residu
involv
mechan
dna
methyl
polyanion
structur
electroposit
bind
region
catalyt
site
due
sever
arginin
residu
also
seem
play
key
role
bind
recognit
key
interact
analogu
aurintricarboxyl
acid
bind
pocket
exploit
structurebas
discoveri
optim
inhibitor
promis
research
tool
studi
enzymat
inhibit
research
cancer
diseas
relat
dna
methyl
follow
studi
includ
evalu
demethyl
agent
cell
base
assay
addit
work
plan
determin
potenti
biochem
activ
aurintricarboxyl
acid
analogu
toward
differ
isoform
dnmt
includ
